JB Pharma enters Opthalmology space, signs Rs 1,089 crore deal with Novartis for 10 brands
Advertisement
New Delhi: JB Chemicals & Pharmaceuticals Ltd (JB Pharma) has announced that the Company has inked a trade mark licence agreement along with promotion and distribution pact with Novartis for select ophthalmology brands entailing a total sum of Rs 1,089 crore.
The acquired brands include Simbrinza, Travatan, Travacom, Azopt, Azarga, Vigamox, Nevanac, Ilevro, Vigadexa, Pataday.
The board of directors at its meeting held on December 19, 2023 approved the execution of a trade mark licence agreement with Novartis Innovative Therapies AG, which is perpetual in nature for the Indian market, for a portfolio of select ophthalmology brands which will be effective in January 2027, JB Pharma said in a regulatory filing.
The board also approved the promotion and distribution agreement with Novartis Healthcare Pvt Ltd for the same portfolio of select ophthalmology brands for the Indian market for a period of three years starting December 2023, it added..
On the financial details of the agreements, JB Pharma said it will pay USD 116 million (Rs 964 crore), excluding applicable taxes, stamp duty and working capital, for the trade marks licence agreement to Novartis Innovative Therapies AG, Switzerland.
Another Rs 125 crore, excluding applicable taxes, stamp duty and working capital, will be paid to Novartis Healthcare Pvt Ltd, India under the promotion and distribution agreement.
"JB Pharma shall offer employment to the impacted associates working on these ophthalmology brands," the filing said.
On the reasons for the acquisition, the company said, "Ophthalmology is one of the fastest growing therapies in the Indian pharma market and this deal will catapult JB Pharma to among the leading players in the ophthalmology segment."
Overall, JB Pharma said the ophthalmology market is a structurally attractive market and major players have registered over 10 per cent value growth with structural tailwinds such as higher cataract surgeries driven by increased infrastructure and rising affordability, growth of 50-plus population and significant under-penetration.
"The brands enjoy strong recall with doctors with perception of better quality as compared to competition," it said.
Citing IQVIA, MAT September, 2023 data, sales for this ophthalmology portfolio was at Rs 207.8 crore, the company said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.